RENAL BIOMARKERS MARKET ANALYSIS

Renal Biomarkers Market, by Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, Urine Albumin), Up-Regulated Proteins (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule 1, Interleukin 18), Others, By Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry), By End User (Diagnostic Labs, Outpatient Clinics, Research Centers, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) -

Published In : Jul 2023
Code : CMI3551
Pages :145
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Regional Analysis

Global Renal Biomarkers Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global renal biomarkers market over the forecast period. North America is estimated to hold 47.5% of the market share in 2023. The North America renal biomarkers market is expected to witness significant growth in the coming years, driven by factors such as the increasing prevalence of CKD and geriatric population leading to the demand for renal biomarkers for kidney disease diagnosis. Consequently, the market for renal biomarkers is expected to increase further during the next years.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa